Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3175034 | 0.99 | CYP3A4 (0.41) | CYP3A4LMNAMAPTL3MBTL1 | |
| SCHEMBL3164557 | 0.95 | CYP3A4 (0.43) | CYP3A4LMNAMAPTL3MBTL1 | |
| SCHEMBL3173949 | 0.94 | CYP3A4 (0.41) | CYP3A4LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4349326 | 0.94 | CYP3A4 (0.42) | CYP3A4LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4342015 | 0.93 | CYP3A4 (0.41) | CYP3A4LMNAMAPTL3MBTL1 | |
| SCHEMBL3158816 | 0.92 | CYP3A4 (0.43) | CYP3A4LMNAMAPTL3MBTL1 | |
| SCHEMBL18857852 | 0.92 | CYP3A4 (0.43) | CYP3A4L3MBTL1 | |
| SCHEMBL3167858 | 0.92 | CYP3A4 (0.43) | CYP3A4LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3165106 | 0.91 | CYP3A4 (0.43) | CYP3A4LMNAMAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3178409 | 0.91 | CYP3A4 (0.42) | CYP3A4LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496053-B1 | Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-06-20 | — | — | EP | claimed |
| US-7642274-B2 | Inhibitor of pain threshold decrease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-05 | — | — | US | claimed |
| US-20070117853-A1 | Inhibitor of pain threshold decrease | SANTEN PHARMACEUTICAL CO., LTD (JP) | 2007-05-24 | — | — | US | claimed |
| US-7112598-B2 | κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-26 | — | — | US | claimed |
| EP-1642590-A1 | PAIN THRESHOLD FALL INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | claimed |
| US-20050113430-A1 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD (JP) | 2005-05-26 | — | — | US | claimed |
| EP-1496053-A1 | KAPPA-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-12 | — | — | EP | claimed |
| US-20170231966-A1 | INHIBITION OF IL-2 PRODUCTION | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9650351-B2 | Inhibition of IL-2 production | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20160046591-A1 | INHIBITION OF IL-2 PRODUCTION | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2016-02-18 | — | — | US | disclosed |
| EP-1496053-B1 | Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-1496053-B1 | Kappa-opioid receptor agonist comprising a 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-7642274-B2 | Inhibitor of pain threshold decrease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-7410987-B2 | Method for treating pain or pruritis by administering κ-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20070117853-A1 | Inhibitor of pain threshold decrease | SANTEN PHARMACEUTICAL CO., LTD (JP) | 2007-05-24 | — | — | US | disclosed |
| US-7112598-B2 | κ opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20060205796-A1 | Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1642590-A1 | PAIN THRESHOLD FALL INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20050113430-A1 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | SANTEN PHARMACEUTICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1496053-A1 | KAPPA-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117853-A1 | Inhibitor of pain threshold decrease | OPRD1, OPRK1, OPRL1 | CYP3A4 1912/4885LMNA 4198/4885MAPT 1463/4885 |
| US-20160046591-A1 | INHIBITION OF IL-2 PRODUCTION | IL2, IL2RA, IL4 | CYP3A4 1489/4885LMNA 4771/4885MAPT 4114/4885 |
| US-20050113430-A1 | Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative | OPRK1, OPRD1, OPRL1 | CYP3A4 361/4885LMNA 4376/4885MAPT 1694/4885 |
| US-20060205796-A1 | Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative | OPRL1, OPRK1, OPRD1 | CYP3A4 701/4885LMNA 4619/4885MAPT 1944/4885 |
| US-20170231966-A1 | INHIBITION OF IL-2 PRODUCTION | IL2, IL2RA, IL4 | CYP3A4 1489/4885LMNA 4771/4885MAPT 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.